Immunovaccine Inc.

Immunovaccine Inc.

May 06, 2014 15:16 ET

Immunovaccine Announces Overnight Marketed Equity Financing

HALIFAX, NOVA SCOTIA--(Marketwired - May 6, 2014) -


Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV) announced today that it has filed a preliminary prospectus in connection with an overnight marketed public offering (the "Offering") of common shares (the "Common Shares"). The Company expects to raise a minimum of $7.5 million in gross proceeds (before any exercise of the Over-Allotment described below) but the size of the Offering will be determined in the context of the market. The Offering will be conducted in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Nova Scotia, and Newfoundland and Labrador and in other jurisdictions in a manner permitted by applicable securities laws and outside of Canada where they may be lawfully sold on a basis exempt from the prospectus and registration requirements of any such jurisdiction.

The Offering will be conducted through a syndicate of underwriters led by Cormark Securities Inc. (the "Underwriters"). The price per Common Share will be determined by the Underwriters and Immunovaccine in the context of the market at the time of entering into a definitive underwriting agreement between the Company and the Underwriters. Immunovaccine has granted to the Underwriters an over-allotment option (the "Over-Allotment Option"), which entitles the Underwriters to acquire at any time up to 30 days following the closing of the Offering, at the same issue price as the Offering, up to an additional 15% of the Common Shares distributed in the Offering.

The Company also intends to simultaneously complete a non-brokered private placement ("Private Placement") of Common Shares for gross proceeds of at least $1 million.

The Company expects to close the Offering and the Private Placement during the week of May 19, 2014, subject to satisfaction of customary closing conditions, including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, such as the final approval of the TSX Venture Exchange.

The net proceeds of the Offering and the Private Placement will be used to advance the research and development and clinical advancement of our DPX-Survivac and DPX-RSV vaccine candidates and for general corporate and working capital purposes.

The Common Shares offered have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Common Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvants to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.

Connect at

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information